What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

About this tracker

What this is, where every number comes from, and what we will not publish.

Method

Eight primary sources are pulled every four hours: the ClinicalTrials.gov v2 registry; Drugs@FDA and the FDA Drug Shortage Database via openFDA; the European Medicines Agency’s register of authorised medicines; Europe PMC; the US Federal Register; and a set of publisher RSS feeds. Every field displayed is taken directly from a source record. Nothing on the trial results, pipeline, regulatory, supply or research pages is written, paraphrased or inferred by a language model. Those pages render the underlying data, and every row links to the record it came from.

What we will not do

We do not reproduce article text or abstracts. We do not publish dosing guidance, efficacy claims that are not attributed to a named study, or anything that reads as medical advice. We do not run affiliate links to telehealth or compounding sellers. We do not mass-generate articles.

Contact

One address, read by a person: [email protected].

Reuse and licensing

The underlying records are not ours to license. Trial registrations from ClinicalTrials.gov and approval and shortage records from openFDA are United States Government works in the public domain, and EMA and Europe PMC records carry their own terms. Those sources are linked from every row so you can go to them directly.

What this site adds is published under CC BY 4.0: the selection of molecules, the arrangement of the tables, and the change history that records what a value was before a source overwrote it. You may republish it, including commercially, provided you credit GLP-1 Briefing and link back to the page you took it from. Attribution as: “GLP-1 Briefing, glp1briefing.com, CC BY 4.0.”

Reuse of the data does not extend to the site’s name or logo, and republishing it does not imply that we endorse or have reviewed what you do with it.

Molecules tracked

semaglutide · tirzepatide · liraglutide · dulaglutide · exenatide · orforglipron · retatrutide · cagrilintide · survodutide · mazdutide · ecnoglutide · maridebart cafraglutide · VK2735 · petrelintide · amycretin · pemvidutide · efinopegdutide · danuglipron · lixisenatide · aleniglipron · olatorepatide · albiglutide

Privacy

This site sets no cookies of its own and asks you for nothing. Our advertising and network providers do collect some data. See what is collected and how to opt out.

Independent project. Not affiliated with the FDA, NIH, Novo Nordisk, Eli Lilly, or any other company or agency named on this site.